AC Immune (NASDAQ: ACIU) and Idera Pharmaceuticals (NASDAQ:IDRA) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk and profitability.
Valuation & Earnings
This table compares AC Immune and Idera Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|AC Immune||$23.55 million||32.58||-$7.20 million||($0.71)||-18.99|
|Idera Pharmaceuticals||$16.20 million||22.46||-$38.38 million||($0.34)||-5.47|
This is a breakdown of current ratings and recommmendations for AC Immune and Idera Pharmaceuticals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
AC Immune presently has a consensus price target of $18.00, suggesting a potential upside of 33.73%. Idera Pharmaceuticals has a consensus price target of $5.40, suggesting a potential upside of 190.32%. Given Idera Pharmaceuticals’ higher possible upside, analysts clearly believe Idera Pharmaceuticals is more favorable than AC Immune.
This table compares AC Immune and Idera Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider & Institutional Ownership
17.1% of AC Immune shares are held by institutional investors. Comparatively, 24.1% of Idera Pharmaceuticals shares are held by institutional investors. 12.4% of Idera Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
AC Immune Company Profile
AC Immune SA is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimer’s and other neurodegenerative diseases, such as Down syndrome, glaucoma and Parkinson’s, and focuses on producing therapeutic and diagnostic product candidates, using SupraAntigen and Morphomer technology platforms. The Company’s pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn, among others.
Idera Pharmaceuticals Company Profile
Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology. Using TLR technology, the Company designs synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. Using its 3GA technology, the Company is developing drug candidates to turn off the messenger ribo nucleic acid (mRNA) associated with disease causing genes. The Company’s drug candidates include IMO-8400, IMO-2125 and IMO-9200. The Company has designed TLR antagonists and agonists to act by modulating the activity of targeted TLRs. It is developing its 3GA technology to turn off the mRNA associated with disease causing genes.
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.